ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Feature|Articles|October 16, 2026
GLP-1s After Breast Cancer: What Nurses Should Ask Survivors
Author(s)Alex Biese
Fact checked by: By ONN Staff
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
Advertisement
Advertisement
Breast cancer survivors are increasingly asking their care teams about glucagon-like peptide-1 (GLP-1) receptor agonists, and two nurses at Winship Cancer Institute of Emory University say the most useful response starts with a question rather than a prescription.
Related to this article
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Oncology nurse April Fowler shares her personal stage 4 cancer journey, reflecting on clinical empathy, patient advocacy, and oncology endurance.
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.
Advertisement
Advertisement